白细胞介素-2 信号在自身免疫和癌症中 T 细胞生物学的调节作用。
Interleukin-2 signaling in the regulation of T cell biology in autoimmunity and cancer.
机构信息
Department of Microbiology and Immunology, Miller School of Medicine, University of Miami, Miami, FL 33136, USA.
Department of Microbiology and Immunology, Miller School of Medicine, University of Miami, Miami, FL 33136, USA.
出版信息
Immunity. 2024 Mar 12;57(3):414-428. doi: 10.1016/j.immuni.2024.02.001.
Abstract
Interleukin-2 (IL-2) is a critical cytokine for T cell peripheral tolerance and immunity. Here, we review how IL-2 interaction with the high-affinity IL-2 receptor (IL-2R) supports the development and homeostasis of regulatory T cells and contributes to the differentiation of helper, cytotoxic, and memory T cells. A critical element for each T cell population is the expression of CD25 (Il2rα), which heightens the receptor affinity for IL-2. Signaling through the high-affinity IL-2R also reinvigorates CD8 exhausted T (Tex) cells in response to checkpoint blockade. We consider the molecular underpinnings reflecting how IL-2R signaling impacts these various T cell subsets and the implications for enhancing IL-2-dependent immunotherapy of autoimmunity, other inflammatory disorders, and cancer.
摘要
白细胞介素-2 (IL-2) 是 T 细胞外周耐受和免疫的关键细胞因子。在这里，我们回顾了 IL-2 与高亲和力 IL-2 受体 (IL-2R) 的相互作用如何支持调节性 T 细胞的发育和稳态，并有助于辅助性、细胞毒性和记忆性 T 细胞的分化。每个 T 细胞群体的一个关键要素是 CD25（Il2rα）的表达，它提高了受体对 IL-2 的亲和力。通过高亲和力 IL-2R 信号转导也能增强 CD8 耗竭 T (Tex) 细胞对检查点阻断的反应。我们考虑了反映 IL-2R 信号如何影响这些不同 T 细胞亚群的分子基础，以及增强依赖 IL-2 的免疫疗法治疗自身免疫、其他炎症性疾病和癌症的意义。
相似文献
1
Interleukin-2 signaling in the regulation of T cell biology in autoimmunity and cancer.
Immunity. 2024 Mar 12;57(3):414-428. doi: 10.1016/j.immuni.2024.02.001.
2
T-bet expressing Tr1 cells driven by dietary signals dominate the small intestinal immune landscape.
bioRxiv. 2025 Jul 4:2025.06.30.662190. doi: 10.1101/2025.06.30.662190.
3
Temporal optimization of CD25-biased IL-2 agonists and immune checkpoint blockade leads to synergistic anticancer activity despite robust regulatory T cell expansion.
J Immunother Cancer. 2025 Aug 11;13(8):e010465. doi: 10.1136/jitc-2024-010465.
4
The Lasting Impact of IL-2: Approaching 50 Years of Advancing Immune Tolerance, Cancer Immunotherapies, and Autoimmune Diseases.
Immunol Invest. 2025 Jul;54(5):589-603. doi: 10.1080/08820139.2025.2479609. Epub 2025 Mar 17.
5
ANV600 is a novel PD-1 targeted IL-2Rβγ agonist that selectively expands tumor antigen-specific T cells and potentiates PD-1 checkpoint inhibitor therapy.
J Immunother Cancer. 2025 Jul 15;13(7):e011905. doi: 10.1136/jitc-2025-011905.
6
IL-18 primes T cells with an antigen-inexperienced memory phenotype for proliferation and differentiation into effector cells through Notch signaling.
J Leukoc Biol. 2024 Dec 31;117(1). doi: 10.1093/jleuko/qiae172.
7
Alteration patterns of peripheral concentrations of cytokines and associated inflammatory proteins in acute and chronic stages of schizophrenia: a systematic review and network meta-analysis.
Lancet Psychiatry. 2023 Apr;10(4):260-271. doi: 10.1016/S2215-0366(23)00025-1. Epub 2023 Feb 27.
8
The extra-islet pancreas supports autoimmunity in human type 1 diabetes.
Elife. 2025 Apr 15;13:RP100535. doi: 10.7554/eLife.100535.
9
Unraveling Cathepsin S regulation in interleukin-7-mediated anti-tumor immunity reveals its targeting potential against oral cancer.
J Biomed Sci. 2025 Jul 24;32(1):69. doi: 10.1186/s12929-025-01154-6.
10
Novel targets for immunotherapy associated with exhausted CD8 + T cells in cancer.
J Cancer Res Clin Oncol. 2023 May;149(5):2243-2258. doi: 10.1007/s00432-022-04326-1. Epub 2022 Sep 15.
引用本文的文献
1
Glucose-dependent glycosphingolipid biosynthesis fuels CD8 T cell function and tumor control.
Cell Metab. 2025 Jul 30. doi: 10.1016/j.cmet.2025.07.006.
2
Causal disentanglement for single-cell representations and controllable counterfactual generation.
Nat Commun. 2025 Jul 23;16(1):6775. doi: 10.1038/s41467-025-62008-1.
3
BLIMP1 negatively regulates IL-2 signaling in T cells.
Sci Adv. 2025 Jul 18;11(29):eadx8105. doi: 10.1126/sciadv.adx8105.
4
Multiple omics-based machine learning reveals peripheral blood immune cell landscape during acute rejection of kidney transplantation and constructs a precise non-invasive diagnostic strategy.
Mamm Genome. 2025 Jul 7. doi: 10.1007/s00335-025-10149-5.
5
Mannan-Rich Fraction Supplementation: A Promising Nutritional Strategy for Optimizing Growth and Health of Pre-Weaning Calves.
Animals (Basel). 2025 Jun 6;15(12):1684. doi: 10.3390/ani15121684.
6
STS2 deficiency revives CD8T cells from exhaustion and augments checkpoint blockade efficacy in cancer immunotherapy.
J Immunother Cancer. 2025 Jun 22;13(6):e010735. doi: 10.1136/jitc-2024-010735.
7
The mechanisms and clinical significance of CD8 T cell exhaustion in anti-tumor immunity.
Cancer Biol Med. 2025 Jun 10;22(5). doi: 10.20892/j.issn.2095-3941.2024.0628.
8
Growth of human regulatory CD4 T cells is more tightly controlled than effector T cells due to distinctive molecular programming.
iScience. 2025 Apr 29;28(6):112553. doi: 10.1016/j.isci.2025.112553. eCollection 2025 Jun 20.
9
Inducible protein degradation reveals inflammation-dependent function of the T cell lineage-defining transcription factor Foxp3.
Sci Immunol. 2025 Jun 6;10(108):eadr7057. doi: 10.1126/sciimmunol.adr7057.
10
Kujigamberol Inhibits IFN-γ and IL-2 mRNA Expression and NFATc2 Binding to Their Promoters in Response to a Phorbol Ester and Ionomycin Stimulation.
Molecules. 2025 May 19;30(10):2214. doi: 10.3390/molecules30102214.
本文引用的文献
1
Stat5 opposes the transcription factor Tox and rewires exhausted CD8 T cells toward durable effector-like states during chronic antigen exposure.
Immunity. 2023 Dec 12;56(12):2699-2718.e11. doi: 10.1016/j.immuni.2023.11.005.
2
Regulatory ILC2-Role of IL-10 Producing ILC2 in Asthma.
Cells. 2023 Oct 31;12(21):2556. doi: 10.3390/cells12212556.
3
Bempegaldesleukin Plus Nivolumab in Untreated Advanced Melanoma: The Open-Label, Phase III PIVOT IO 001 Trial Results.
J Clin Oncol. 2023 Oct 20;41(30):4756-4767. doi: 10.1200/JCO.23.00172. Epub 2023 Aug 31.
4
IL-2Rα-biased agonist enhances antitumor immunity by invigorating tumor-infiltrating CD25CD8 T cells.
Nat Cancer. 2023 Sep;4(9):1309-1325. doi: 10.1038/s43018-023-00612-0. Epub 2023 Aug 7.
5
Robust IL-2-dependent antitumor immunotherapy requires targeting the high-affinity IL-2R on tumor-specific CD8 T cells.
J Immunother Cancer. 2023 Jun;11(6). doi: 10.1136/jitc-2022-006611.
6
A systematic review of interleukin-2-based immunotherapies in clinical trials for cancer and autoimmune diseases.
EBioMedicine. 2023 Apr;90:104539. doi: 10.1016/j.ebiom.2023.104539. Epub 2023 Mar 31.
7
How autoreactive thymocytes differentiate into regulatory versus effector CD4 T cells after avoiding clonal deletion.
Nat Immunol. 2023 Apr;24(4):637-651. doi: 10.1038/s41590-023-01469-2. Epub 2023 Mar 23.
8
Batf stabilizes Th17 cell development via impaired Stat5 recruitment of Ets1-Runx1 complexes.
EMBO J. 2023 Apr 17;42(8):e109803. doi: 10.15252/embj.2021109803. Epub 2023 Mar 14.
9
Principles of regulatory T cell function.
Immunity. 2023 Feb 14;56(2):240-255. doi: 10.1016/j.immuni.2023.01.004.
10
Bispecific PD1-IL2v and anti-PD-L1 break tumor immunity resistance by enhancing stem-like tumor-reactive CD8 T cells and reprogramming macrophages.
Immunity. 2023 Jan 10;56(1):162-179.e6. doi: 10.1016/j.immuni.2022.12.006.
Zotero 插件